Background. RhoB is a member of the Rho small GTPase family that regulates cytoskeletal dynamics and vesicle trafficking. The RhoB homologs, RhoA and RhoC, have been shown to promote cancer progression and metastasis. In contrast, the functions of RhoB in human cancers are context dependent. Although expression of RhoB inversely correlates with disease progression in several epithelial cancers, recent data suggest that RhoB may support malignant phenotypes in certain cancer types.
RhoB and its close homologs, RhoA and RhoC, belong to the Rho small GTPase family. Similar to the related Ras GTPases, these proteins are also molecular switches that regulate downstream effector molecules via cycling between GTP-and GDP-bound states. Rho GTPases are crucial regulators of actin dynamics and play a central role in mediating signal transduction from extracellular stimuli that target cytoskeleton. 1 Regulation of the actin cytoskeleton by Rho GTPases has diverse impacts on cell mobility, vesicle trafficking, and cell-cycle progression. Although genes encoding Rho GTPases are rarely mutated in human cancers, changes in expression of Rho GTPases are extensively documented. RhoA and RhoC are upregulated in a number of cancer types with potential roles in proliferation, survival, and metastasis. 2, 3 In contrast, evidence for the role of RhoB in tumorigenesis remains controversial. Early studies suggest that RhoB may promote Ras-induced transformation. 4, 5 However, immunohistochemical stainings show that expression of RhoB inversely correlates with tumor grade and invasiveness in gastric cancer, head and neck squamous carcinoma, and lung cancer, 6 -9 suggesting potential tumor suppressive functions of RhoB in these cancers. Knockout of RhoB in mice does not affect normal biological functions but increases susceptibility to carcinogen-induced skin tumorigenesis. 10 Nonetheless, emerging evidence suggests potential roles of RhoB in supporting tumorigenic functions.
For example, RhoB expression is upregulated in T-acute lymphoblastic leukemia cells in comparison with normal T cells. 11 High RhoB expression is found to associate with poor survival in lung adenocarcinoma. 12 Depletion of RhoB in lung cancer cells impairs metastatic potential and increases sensitivity to chemoradiotherapy. 12 In addition, activation of RhoB appears to protect cancer cells from radiation-induced apoptosis and mitotic cell death. 13 -15 RhoB induction by nongenotoxic stresses also appears to improve cellular survival, potentially via activation of NF-kB. 16, 17 These observations collectively suggest that the roles of RhoB in human cancer are context dependent.
In glioma, the expression patterns and functions of RhoB remain largely unknown. Forget et al have analyzed expression of RhoA, RhoB, and Rac1 by immunoblotting tumor homogenates derived from patients with gliomas of different stages. 18 Their results indicated reduced protein levels of all 3 of these GTPases in tumors relative to normal brain tissues, despite several prior studies suggesting upregulation of RhoA and Rac1 in several cancer types. 19 Furthermore, expression of the Rho GTPases inversely correlated with tumor grade, with glioblastoma exhibiting the lowest expression. 18 However, data derived from The Cancer Genome Atlas (TCGA) and the Repository for Molecular Brain Neoplasia Data (REMBRANDT) do not suggest significant changes of RhoB at DNA or mRNA levels in glioma. Other studies have suggested possible tumorigenic functions of RhoB in glioblastoma. In the U87 glioblastoma cell line, RhoB is activated following hypoxic stimulus and is required for stabilization of the hypoxia-inducible factor-1a, which is a key promoter of glioblastoma pathogenesis. 20 The same group further demonstrated that the avb3 and avb5 integrin-focal adhesion kinase pathways regulate glioblastoma response to hypoxia via activation of RhoB, 21 suggesting that RhoB regulates a mechanistic link between extracellular matrix and hypoxic response. In addition, the same integrins also regulate glioblastoma response to ionizing radiation through activation of RhoB. 22 Increased expression of avb3 integrin, the positive RhoB regulator, is associated with poor prognosis in glioblastoma. 23 These results suggest potential oncogenic activities of RhoB in glioblastoma. In the present study, we investigated the expression and functions of RhoB in a panel of glioblastoma surgical specimens and primary xenograft lines. Our results demonstrated important functions of RhoB in proliferation and survival of glioblastoma cells and in key signal transduction pathway including p53 and STAT3.
Materials and Methods

Tumor Samples and Cell Culture
Glioma surgical specimens were provided by the Vanderbilt (University) Molecular Neurosurgical Tissue Bank in accordance with protocols approved by the institutional review board. Two normal neural tissue samples were acquired from patients undergoing epilepsy surgery. VU10369 and VU10827 are established as primary xenograft lines, and VU11044 is a primary culture. GBM12, GBM22, GBM46, and GBM59 xenograft lines are established at Mayo Clinic. 24 Additional primary xenograft lines, T4105, T4302, T4743, and CW619, were provided by Jeremy Rich at Cleveland Clinic. These primary xenograft lines were serially passaged as subcutaneous tumors in immunocompromised mice. All glioblastoma ex vivo cultures were maintained in neurobasal medium supplemented with B27 serum substitute, 20 ng/mL EGF, and 20 ng/mL bFGF (Life Technologies).
DNA Construct and Lentivirus Production
The complementary DNA encoding human RhoB was amplified by PCR from pCDNA3-RhoB provided by Said Sebti at Moffitt Cancer Center. RhoB-V14 was amplified by PCR from pEGFP-Endo-RhoB-V14 provided by Gerard Apodaca at University of Pittsburgh. Both DNA sequences were inserted into the XbaI and EcoRI sites of the lentiviral vector pCDH-CMV-MCS-EF1-Puro (System Biosciences). The pLKO.1 expression vectors for RhoBtargeted short hairpin RNA (shRNA) sequences (shRhoB-1: TRCN0000047851 and shRhoB-2: TRCN0000047852) were purchased from Thermo Scientific. Lentivirus was produced by cotransfection of 293T cells with the packaging vectors psPAX2 and pCI-VSVG (Addgene) using Lipofectamine 2000 (Life Technologies). Following lentiviral infection, glioblastoma cells were selected with 1 mg/mL puromycin for 48 hours before the experiments.
Antibodies and Other Reagents
RhoB antibody (#sc-180) was purchased from Santa Cruz Biotechnology. Mouse monoclonal antibody against actin (#MAB1501) was purchased from Millipore. Monoclonal antibody against p53 (DO-1) was purchased from Sigma. Other antibodies, including phospho-Y705 Stat3 (#9145), Stat3 (#9139), and p21 (#2946) were purchased from Cell Signaling Technology. Recombinant human LIF (#300-05) and IL-6 (#200-06) were purchased from Peprotech.
Cell Growth Assays
Glioblastoma cells were plated in triplicate at 5000 cells per well in 96-well plates. The number of viable cells was measured using the CellTiter-Glo Luminescent Cell Viability Assay Kit (Promega) at 1, 3, and 5 days after plating. The luminescence reading was normalized to 1 mM ATP solution. To determine the relative cell growth rate, the mean cell titer values of each experimental arm on day 1 were assigned a value of 1. All subsequent cell titer values were normalized accordingly.
Cell Cycle Distribution and Apoptosis
To determine cell cycle distribution, cells were fixed in 75% ethanol for 30 minutes at room temperature and then stained using 10 mg/mL propidium iodide. Cells were analyzed on a BD Science LSRFortessa cell analyzer. Cell cycle distribution was calculated using ModFit LT software.
The activities of caspase-3/7 were measured by the CaspaseGlo 3/7 assay kit (Promega) according to the manufacturer's instructions. Caspase activities were normalized to the corresponding cell titers in replicate wells to determine the relative caspase 3/7 activities. In addition, apoptotic cells were labeled by the FITC-conjugated Annexin V staining kit (BD Biosciences) according to manufacturer's instructions and analyzed by flow cytometry.
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Intracranial Glioblastoma Model
Animal experiments were performed in accordance with a protocol approved by the Vanderbilt University Institutional Animal Care and Use Committee. T4302 and VU10827 cells were infected with lentivirus, directing expression of RhoB-targeted shRNA sequences and selected with 1 mg/mL puromycin for 2 days. Five thousand T4302 or 20 000 VU10827 cells were suspended in 10 mL phosphate buffered saline and implanted into the right cerebrum of athymic nude mice to induce intracranial tumors. Following tumor implantation, mice were maintained until development of overt neurological symptoms, such as significant weight loss, lethargy, and/or hunched posture. Median survival was determined by the Kaplan-Meier estimator using GraphPad Prism 5.0 Software.
Results
RhoB Is Expressed in High-grade Glioma
We analyzed RhoB protein levels in a group of 8 glioma surgical specimens and compared them with 2 specimens derived from patients with epilepsy. All samples were diagnosed as glioblastoma except VU11067, which was a grade II oligodendroglioma. Immunoblot of tumor homogenates identified similar RhoB expression in glioma tumors as in epilepsy surgical specimens (Fig. 1A) . We further investigated RhoB expression in a large panel of subcutaneous glioblastoma xenograft tumors (Supplementary, Fig. S1A ). RhoB protein was readily detected in the majority of samples, although the levels varied. Lastly, we examined RhoB expression in short-term ex vivo cultures derived from xenograft tumors as well as a low-passage primary culture directly derived from a glioblastoma surgical specimen, VU11044 (Fig. 1B) . Cells derived from these samples were maintained in serum-free and growth factor-supplemented media known to preserve the genotypic and phenotypic characteristics of parental tumors. 25 Significant levels of RhoB protein were detected in all cultures, with the exception of CW619. Interestingly, the mRNA level of RhoB in CW619 was similar to those identified in other lines (Supplementary, Fig. S1B ), suggesting that RhoB could be regulated by posttranslational mechanisms in this line. Collectively, these results suggest that RhoB expression is maintained in the majority of high-grade glioma tumors.
Depletion of Endogenous RhoB Impairs Proliferation and Survival of Glioblastoma Cells
Both oncogenic and tumor-suppressive functions have been described for RhoB. To investigate the functions of RhoB in glioblastoma, we assessed the loss of RhoB function and the resulting impact using 2 previously published shRNA sequences ( Fig. 2A and Supplementary, Fig. S2A ). 26 Knockdown of RhoB significantly reduced cell growth in multiple lines of glioblastoma ex vivo cultures ( Fig. 2B and Supplementary, Fig. S2B -D) . The ability of T4302 glioblastoma cells to form neurospheres was completely abolished with reduced RhoB expression (data not shown). In contrast, expression of these RhoB-specific shRNA sequences did not exhibit any apparent impact on the growth of the RhoB low line, CW619 (Supplementary, Fig. S2E ). These results suggest that RhoB is broadly implicated in proliferation and survival of glioblastoma cells, although it can be dispensable in a small subset of tumors.
RhoB and several other members of the Rho family GTPases are known to regulate cell cycle progression. 19 For example, farnesylated RhoB partially rescues NIH-3T3 cells from cell cycle arrest induced by inhibition of geranylgeranyltransferase, which regulates an alternative form of prenylation for many membrane-associated proteins including Ras family proteins. 27 To further understand the oncogenic functions of RhoB in glioblastoma, we investigated whether knockdown of RhoB affected cell cycle progression. Expression of the shRNA sequences targeting RhoB reduced the proportions of cells in S phase with concomitant increases in the cellular subpopulation in G1 phases in T4302 (Fig. 2C and Supplementary, Fig. S3A ). Depletion of RhoB in VU10827 also decreased proliferating cells in S phase but induced cell arrest in both G1 and G2/M phases (Supplementary, Fig. S3A and B) . In addition to cell cycle arrest, knockdown of RhoB was associated with induction of Annexin V, an early apoptotic maker (Fig. 2D) . Activation of apoptosis was also indicated by increased caspase 3/7 activities in cells with compromised RhoB expression (Fig. 2E) .
Knockdown of RhoB Impairs Tumorigenic Potential of Glioblastoma Cells
The results described above suggest that RhoB has crucial functions in maintaining malignant phenotypes of glioblastoma. We next sought to determine whether knockdown of RhoB affects the ability of glioblastoma cells to generate intracranial tumors in immunocompromised mice. The cells utilized were derived from 2 primary glioblastoma xenograft lines: T4302 and VU10827. Stable knockdown of RhoB was established by lentivirus-mediated expression of shRNA followed by selection for puromycin-resistant cells. Once reduction of RhoB expression was confirmed by qRT-PCR, cells were implanted into the right cortex of athymic nude mice. Mice implanted with control cells consistently developed neurological signs shortly after 1 month (Fig. 3A and B and Supplementary, Fig. S4 ). In contrast, animals implanted with cells expressing RhoB-specific shRNA sequences survived significantly longer in both experiments (P , .05 by the log-rank test). Although tumors eventually developed in animals implanted with RhoB-knockdown cells, we found that RhoB expression was restored in these tumors (Fig. 3C) . These tumors were possibly derived from cells that did not maintain shRNA expression. For mice implanted with VU10827 cells, one mouse of (Fig. 3D) . In contrast, examination of the mouse implanted with cells expressing RhoB shRNA-2 showed only a small tumor with well-circumvented borders near the injection site (Fig. 3E) . Additionally, the mouse implanted with cells expressing RhoB shRNA-1 appeared to be free of tumor when euthanized (data not shown). Taken together, these results suggest that the functions of RhoB are required to maintain tumorigenic potential of glioblastoma cells in vivo.
Ectopically Expressed RhoB or an Active Mutant Does Not Significantly Affect Glioblastoma Cells
Increased expression of RhoB appears to antagonize oncogene-induced transformation and represses proliferation, survival, and metastasis of cancer cells in several studies. 28 -30 However, ectopic expression of RhoB or RhoB mutants in these studies is mediated by plasmids, which may produce excessive RhoB proteins and result in unidentified off-target effects that impair cellular functions. As such, we introduced RhoB and an active RhoB mutant, RhoB-V14, into glioblastoma cells by lentiviral infection. Lentivirus-directed expression of RhoB was under control of the cytomegalovirus (CMV) promoter with resulting expression levels several folds higher than the endogenous protein levels in T4302 cells (Fig. 4A) . Minimal impact on growth or cell cycle progression of T4302 cells was observed following lentivirusmediated expression of RhoB or RhoB-V14 (Fig. 4B and C) . In addition, the RhoB low line, CW619, did not significantly respond to ectopic RhoB expression (Fig. 4D) . On the basis of these observations, RhoB does not exhibit apparent tumor suppressor features in glioblastoma.
Knockdown of RhoB Activates p53 and Induces p21
Depletion of RhoB resulted in a G1 cell cycle arrest in T4302 cells and a G2/M arrest in VU10827 cells. The CDK inhibitor p21 CIP1/ WAF1 is a potent inducer of G1 cell cycle arrest. Immunoblotting demonstrated that p21 was significantly induced in T4302 cells following RhoB knockdown but was surprisingly downregulated in VU10287 cells (Fig. 5A) . Induction of p21 transcription upon RhoB knockdown in T4302 cells was validated by qRT-PCR (Fig. 5B) . We further demonstrated that p53, the major transcription factor of p21, was accumulated in T4302 cells following RhoB knockdown (Fig. 5A) . In contrast, p53 proteins could not be detected in VU10827 regardless of their RhoB status (Fig. 5A) . However, p53 mRNA was readily detected in VU10287 cells (Fig. 5B) . We sequenced the p53 gene in VU10827 cells and identified a nonsense mutation at the residue Trp91 (TGG to TGA) that resulted in a premature stop codon (data not shown). In CW619 cells, both p21 and p53 levels were very low and irresponsive to expression of RhoB shRNA sequences (Fig. 5A) . These results suggest that disruption of RhoB-regulated functions in glioblastoma leads to activation of p53-mediated surveillance mechanisms. However, additional signaling pathways are regulated by RhoB, as tumors without functional p53 are also affected by depletion of RhoB.
RhoB Regulates STAT3 Signaling in Glioblastoma
RhoB is crucially implicated in trafficking of a range of signaling molecules that play important roles in gliomagenesis, including membrane-bound growth factor receptors (eg, EGFR and PDGFRB) cytokine receptors (eg, CXCR2), 31 -33 and cytoplasmic signaling proteins (eg, SRC). 34 A common downstream target of these pathways is STAT3, which is known to have critical functions in glioblastoma, particularly in the cancer stem cell subpopulation. 35, 36 We next investigated how loss-of-function of RhoB affected basal STAT3 signaling in glioblastoma. Our results demonstrated that knockdown of RhoB decreases the phosphorylation levels of STAT3 at the key activation residue Tyr705 in multiple glioblastoma lines (Fig. 6A) . Again, phosphorylation of Tyr705 was not altered by RhoB shRNA sequences in the RhoB low line, CW619 (Fig. 6A) . The interleukin-6 family cytokines, such as interleukin-6 (IL-6) and leukemia inhibitory factor (LIF), are major STAT3 activators. 37 Stimulation of T4302 cells with IL-6 or LIF resulted in significant increases in the levels of phosphorylated STAT3, which were markedly compromised by expression of RhoB-specific shRNA sequences (Fig. 6B) . Taken together, these data identify a novel link between RhoB and the STAT3 signaling pathway that is commonly activated in glioblastoma. As such, the functions of RhoB in p53-null glioblastoma tumors can be mediated, at least in part, via the STAT3 pathway.
Discussion
The RhoB small GTPase has been traditionally viewed as a tumor suppressor in epithelial cancers, mostly due to the observations that RhoB expression levels inversely correlate with tumor grade in several cancer types. 6 -9 However, there is generally a lack of functional and mechanistic understanding of RhoB in human cancers. Emerging evidence suggests that RhoB is not always downregulated in cancer and that it can be implicated in maintenance of malignant phenotypes. In breast cancer, Fritz et al showed that protein levels of several Rho GTPases, including RhoB, was upregulated in comparison to adjacent normal tissues. 38 Halon et al also reported elevated RhoA and RhoB expression in a group of 85 grade II breast cancer patients. 39 In contrast, Medale-Giamarchi et al reported that RhoB expression inversely correlated with breast tumor grade and tumor size. 40 However, their results also suggested that RhoB positively regulated expression of estrogen receptor alpha and selectively promoted proliferation of estrogen receptor-positive breast cancer cell lines. 40 More recently, Luis-Raveloe et al reported that RhoB promoted tumor metastasis and resistance to chemoradiotherapy in lung adenocarcinoma. 12 Their results demonstrated that knockdown of RhoB substantially reduced the burden of metastatic lesions in tumor-bearing mice and prolonged survival. 12 The complexity of RhoB's roles in human cancers is further demonstrated by recent findings that RhoB negatively regulated AKT signaling in breast cancer cells but promoted AKT activity in stromal endothelial cells. 41 Interestingly, the negative impact of RhoB on proliferation of early stage cancer was superseded by the proangiogenic functions of RhoB during tumor progression. 41 While these paradoxical observations may partially stem from differences in methods and materials, they collectively suggest that the functions of RhoB in cancer are highly context dependent.
Little is known about the expression patterns of RhoB in glioblastoma. An earlier study, using autopsy brain samples as normal controls, suggested that RhoA, RhoB, and Rac1 expression were downregulated in glioma. 18 However, in this context, postmortem stress and associated hypoxia may have resulted in elevation of RhoB levels in the control samples, as suggested by previous findings. 20, 42 In the present study, we demonstrated similar RhoB protein levels between glioblastoma tissues and nonmalignant neural tissues obtained from epilepsy surgery. RhoB expression was also identified in the majority of Our results showed that knockdown of RhoB in glioblastoma cells results in cell cycle arrest, activation of apoptosis, and loss of tumorigenic potential. Similar observations were made across a panel of glioblastoma primary xenograft lines irrespective of their genetic backgrounds, with the exception of CW619, which is a line having very low RhoB protein levels. However, ectopic expression of RhoB or the constitutively active RhoB-V14 mutant did not promote glioblastoma cell growth or affect p53 and STAT3 (Supplementary, Fig. S5 ). These results suggest that RhoB is not a rate-limiting oncogenic factor in glioblastoma, unlike a typical oncogene. This phenomenon can be explained by the nononcogene addiction model. This model suggests that nononcogenes are not frequently altered at genomic levels in cancer because alterations of these genes do not provide additional benefits to cancer development. 43 However, the products of these nononcogenes are required to maintain tumorigenic activities, often by neutralizing various stresses to cancer cells. Nononcogenes can also be exploited as therapeutic targets. For example, BRCA2-mutated cancers are defective in homologous recombinationmediated DNA damage repair and thus become highly sensitive to inhibition of poly(ADP-ribose) polymerase that compensates for the loss of BRCA2 activity. 44 RhoB is known to protect cells from cell death induced by DNA damage 13 -15 and nongenotoxic stresses. 16, 17 Our data showed that depletion of RhoB activated the stress sensor p53 and consequently induced p21 expression, cell cycle arrest, and apoptosis. These results suggest that RhoB is broadly required to maintain important biological functions of glioblastoma cells and that depletion of RhoB may result in stress phenotypes. Taken together, our study suggests a nononcogene addiction to RhoB in glioblastoma. However, the exact type of stress regulated by RhoB remains to be identified.
Depletion of RhoB compromised STAT3 signaling in glioblastoma irrespective of p53 status. Activation of STAT3 by either IL-6 or LIF was also attenuated in the absence of RhoB. STAT3 is a pleiotropic transcription factor implicated in many biological processes ranging from immune response to neural tissue differentiation. 45 It is frequently activated in glioblastoma and many other cancers through a wide range of receptors for cytokines and growth factors. 45 Of particular interest, STAT3 appears to play a crucial role in maintaining the cancer stem cell subpopulation of glioma. 35, 36 STAT3 signaling is affected by a diverse array of microenvironmental and intrinsic signals 37 . It has been reported that several Rho small GTPases are implicated in regulation of STAT3 activity, such as RhoA, Rac1, and Cdc42. 46 Rac1 is thought to directly bind to STAT3, 47 although this interaction may be context dependent. 48 Alternatively, Rho GTPases may cross talk with kinases upstream of STAT3, such as SRC and JAK2. 49 Our study identified a novel role for RhoB in maintaining full STAT3 activity in glioblastoma. The detailed mechanisms through which RhoB regulates STAT3 in glioblastoma remain to be characterized and potentially involve molecules mediating cross talks between STAT3 and other Rho GTPases.
In summary, our results have identified novel functions of RhoB in maintening tumorigenic activities in glioblastoma. However, molecular mechanisms underlying the tumor-promoting functions of RhoB are just beginning to emerge. High throughput technologies, such as analyses of transcriptome or proteome, are expected to provide more in-depth mechanistic insights into the roles of RhoB in glioblastoma. Nevertheless, our data suggest that RhoB supports tumor tolerance to cellular and environmental stresses, at least in part via regulation of p53 and STAT3 pathways, thus highlighting its potentials as a therapeutic target. However, pharmacological targeting of small GTPases, like RhoB, has proven to be challenging. Farnesyltransferase inhibitors only partially suppress RhoB, which exists in both farnesylated and geranylgeranylated forms. 50 A better understanding of RhoB in glioblastoma and development of alternative inhibitors will be required to fully exploit this pathway.
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